Deucravacitinib Long-Term Efficacy Through 4 years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 4, p. s408, 2024. DOI: 10.25251/skin.8.supp.408. Disponível em: https://skin.dermsquared.com/skin/article/view/2872. Acesso em: 20 apr. 2026.